1439896-97-5

Usage

Uses

Used in Pharmaceutical Industry:
Fenoprofen is used as an analgesic and anti-inflammatory agent for the treatment of conditions such as arthritis and menstrual cramps. Its ability to reduce inflammation and alleviate pain makes it a valuable medication in managing these conditions.
Used in Pain Management:
Fenoprofen is utilized as a pain reliever to address mild to moderate pain. Its effectiveness in reducing pain levels makes it suitable for various applications where pain management is required.
Used in Oral Dosage Forms:
Fenoprofen is available in various oral dosage forms, including tablets and capsules, making it convenient for patients to take as directed by healthcare professionals.

Upstream product

• 547-63-7 Methyl isobutyrate 
• 402-49-3 4-bromomethyltrifluoromethylbenzene 
• 1607004-51-2 ethyl 2,2-dimethyl-3-[4-(trifluoromethyl)phenyl]propanoate 
• 1607004-50-1 ethyl 2-methyl-3-[4-(trifluoromethyl)phenyl]propanoate 
• 890648-41-6 2-methyl-3-(4-trifluoromethyl-phenyl)-acrylic acid ethyl ester 
• 455-19-6 4-Trifluoromethylbenzaldehyde 
• 939-99-1 4-trifluoromethylbenzyl chloride 
• 14248-25-0 2,2-Dimethyl-3-(p-trifluormethylphenyl)-propionsaeuremethylester 

Downstream Products

• 1607004-37-4 N-[[(4R)-4-cyclopropyl-2,5-dioxo-imidazolidin-4-yl]methyl]-2,2-dimethyl-3-[4-(trifluoromethyl)phenyl]propanamide 

Relevant academic research and scientific papers

Direct β-C(sp3)-H Acetoxylation of Aliphatic Carboxylic Acids

The controlled construction of defined oxidation patterns is one of the key aspects in the synthesis of natural products and bioactive molecules. Towards this goal, we herein report a novel protocol for the Pd-catalyzed direct β-C(sp3)-H acetoxylation of aliphatic carboxylic acids. The protocol enables the use of free carboxylic acids in one step and without the need of introducing specialized strong directing groups. In our studies, we found that the use of a "traceless base" was crucial for the development of a synthetically useful transformation. Furthermore, the synthetic utility of the products obtained was demonstrated by their use in subsequent transformations.

A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose

Aggrecanase-1 and -2 (ADAMTS-4 and ADAMTS-5) are zinc metalloproteases involved in the degradation of aggrecan in cartilage. Inhibitors could provide a means of altering the progression of osteoarthritis. We report the identification of 7 which had good oral pharmacokinetics in rats and showed efficacy in a rat chemical model of osteoarthritis. The projected human dose required to achieve sustained plasma levels ≥10 times the hADAMTS-5 IC50 is 5 mg q.d.

AGGRECANASE INHIBITORS

The present invention provides compounds having the formula: wherein R1 is selected from methyl, ethyl, propyl, cyclopropyl, and dimethyl, or a pharmaceutically acceptable salt thereof, along with methods and intermediates for their preparation, and uses thereof.

Sulfoximine assisted Pd(II)-catalyzed bromination and chlorination of primary β-C(sp3)-H bond

S-Methyl-S-2-pyridyl-sulfoximine (MPyS) directed bromination and chlorination of the 1°-β-C(sp3)-H bond of MPyS-N-amides is realized under the influence of N-Br/Cl-phthalimides and a Pd(II)-catalyst. The sequential halogenation and acetoxylation of α-dimethyl MPyS-N-amides constructs highly functionalized α-trisubstituted aliphatic acid derivatives. The MPyS directing group is cleaved from the halogenated products and recovered. (Chemical Equation Presented).

Highly regioselective carbonylation of unactivated C(sp3)-H bonds by ruthenium carbonyl

The regioselective carbonylation of unactivated C(sp3)-H bonds of aliphatic amides was achieved using Ru3(CO)12 as a catalyst. The presence of a 2-pyridinylmethylamine moiety in the amide is crucial for a successful reaction. The reaction shows a preference for C-H bonds of methyl groups as opposed to methylene C-H bonds and tolerates a variety of functional groups. The stoichiometric reaction of an amide with Ru 3(CO)12 gave a dinuclear ruthenium complex in which the 2-pyridinylmethylamino moiety was coordinated to the ruthenium center in an N,N manner.